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Abstract
Purpose Little is known about the occurrence, timing and
prognostic factors for first and also subsequent local (LR),
regional (RR) or distant (DM) breast cancer recurrence. As
current follow-up is still consensus-based, more informa-
tion on the patterns and predictors of subsequent recur-
rences can inform more personalized follow-up decisions.
Methods Women diagnosed with stage I-III invasive breast
cancer who were treated with curative intent were selected
from the Netherlands Cancer Registry (N = 9342). Exten-
ded Cox regression was used to model the hazard of
recurrence over ten years of follow-up for not only site-
specific first, but also subsequent recurrences after LR orRR.
Results In total, 362 patients had LR, 148 RR and 1343
DM as first recurrence. The risk of first recurrence was
highest during the second year post-diagnosis (3.9%; 95%
CI 3.5–4.3) with similar patterns for LR, RR and DM.
Young age (\40), tumour size[2 cm, tumour grade II/III,
positive lymph nodes, multifocality and no chemotherapy
were prognostic factors for first recurrence. The risk of
developing a second recurrence after LR or RR (N = 176)
was significantly higher after RR than after LR (50 vs 29%;
p\ 0.001). After a second LR or RR, more than half of the
women were diagnosed with a third recurrence.
Conclusions Although the risk of subsequent recurrence is
high, absolute incidence remains low. Also, almost half the
second recurrences are detected in the first year after pre-
vious recurrence and more than 80% are DM. This suggests
that more intensive follow-up for early detection subse-
quent recurrence is not likely to be (cost-)effective.
Keywords Breast cancer  Recurrence patterns 
Recurrence risk  Follow-up  Prognostic factors
Introduction
As a result of early detection and improved treatment,
survival after breast cancer has improved significantly.
Consequently, an increasing number of women is in need
of follow-up care after curative treatment [1]. The main
aim of follow-up is the early detection of local (LR) or
regional recurrences (RR) and secondary primary tumours
[2]. The incidence of first recurrence is influenced by
prognostic factors such as age, grade, nodal involvement,
hormone receptor status and treatment of the primary
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tumour [3, 4]. Patients with LR or RR have a higher risk of
developing distant metastasis (DM) and have worse sur-
vival compared to patients without LR or RR [5–9].
Information on the pattern of site-specific first and second
recurrence after LR or RR is lacking and the effect of
prognostic factors such as the disease-free interval (DFI)
after a first LR or RR on the development of subsequent
recurrences is not well documented. Earlier studies showed
a peak in first recurrence hazard approximately two years
after the primary tumour [10–12]. Some studies also
demonstrated a second peak between 4–9 years after
treatment, mainly in ER-positive patients [10–16]. How-
ever, these studies lack contemporary treatments [11] or
report single-institution data [12–16]. Also the pattern of
subsequent recurrence after the first is not yet analysed.
The pattern of recurrence risk and prognostic factors for
the development of subsequent breast cancer recurrences
can provide valuable information for informed clinical
decision-making and patient centred follow-up. Using a
population-based cohort of women with follow-up data of
ten years after treatment for primary invasive breast cancer,
we aimed to (1) analyse the occurrence and timing of not
only first, but also subsequent LR, RR and DM, (2) identify
prognostic factors for first and subsequent LR, RR and DM
and (3) identify consequences of these patterns for tailoring
of follow-up.
Patients and methods
Data collection and study population
Data originate from the nationwide population-based
Netherlands Cancer Registry (NCR), for which data are
collected directly from patient medical records by a team
of specially trained data managers. All data are registered
in accordance with national and international coding rules,
and include patient, primary tumour and treatment char-
acteristics, as well as data concerning tumour recurrences
within ten years following diagnosis.
Women with primary invasive breast cancer diagnosed
in Dutch hospitals in 2003 were included (N = 10,356).
Eligibility criteria were stage I–III breast cancer, no pre-
vious or synchronous cancer, no direct extension to chest
wall or skin, surgical treatment in a Dutch hospital and no
neo-adjuvant therapy. Patients with macroscopic residue
after surgical treatment or microscopic residue without
adjuvant treatment were excluded.
End-points
Site of recurrence was classified as follows: (1) local—any
epithelial breast cancer or ductal carcinoma in situ (DCIS)
in ipsilateral breast tissue, or in skin and subcutaneous
tissue of the ipsilateral thoracic wall, (2) regional—breast
cancer in ipsilateral lymph nodes or contralateral lymph
nodes if axillary lymph node dissection was performed, or
(3) distant—breast cancer in any other location except the
contralateral breast [17].
Only patients with LR or RR as first recurrence were
considered at risk for subsequent LR, RR or DM. Subse-
quent recurrences after DM were not taken into account, as
DM is considered incurable and further LR or RR has no
consequence. For patients with synchronous recurrences,
the most life-threatening site of recurrence was taken as
endpoint: in case of synchronous LR and RR, the recur-
rence was registered as RR; when DM was diagnosed with
LR or RR, DM was registered. Within the NCR, tumours
detected within three months after diagnosis of the previ-
ous tumour were considered synchronous. Therefore, fol-
low-up time started three months after diagnosis of the
primary tumour. The time to first recurrence or disease-free
interval (DFI) was measured from three months after
diagnosis of the primary tumour to date of detection of
recurrence at any site. DFI to second and third recurrence
was measured from detection of the previous recurrence to
detection of subsequent recurrence. Follow-up time was
censored at ten years after start of follow-up. In addition,
survival analyses were performed per type of recurrence
for survival after the primary tumour, after first and after
second recurrence.
Prognostic factors
Variables were selected based on literature and availability
of the data. Estrogen receptor (ER) and progesterone
receptor (PR) status were combined into one prognostic
factor (ER or PR positive, ER and PR negative) [18]. Age
at diagnosis of the primary tumour (\40, 40–49,
50–75,[75), size (B2, [2–5, C5 cm), grade (I, II, III),
histological type (ductal, lobular or other), multifocality
(yes, no), lymph node status (negative, 1–3, 4–9 nodes),
hormone receptor status, type of surgery (breast conserving
(BCS) or mastectomy), chemo-, endocrine and radiation
therapy (all yes or no) of the primary tumour were assessed
as prognostic factors for first recurrence. The same patient,
primary tumour and treatment characteristics, DFI and
treatment of the recurrence (surgery, chemo-, radiation, and
endocrine therapy) were analysed as prognostic factors for
subsequent recurrence.
Statistical analysis
The number of recurrences at specific recurrence sites were
compared using the Wilcoxon rank sum test. We identified
prognostic factors for site-specific first recurrence and
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subsequent recurrences after LR or RR using extended Cox
regression analysis. A minimum hazard ratio (HR) of 1.1
was used for inclusion in the multivariable analysis. To
avoid overfitting, an effective sample size of ten per esti-
mated parameter was used, excluding the ones with the
smallest effect first [19]. Variables that were significant
when testing the proportional hazards assumption by means
of Schoenfeld residuals and non-parallel on the log–log
plot of the DFI were included as time-varying coefficients
in the extended Cox model. Cox regression was also used
for modelling the survival after the primary tumour and the
first and second recurrence. With the logrank test, the
equality of the survival functions was tested.
Prognostic factors with missing values were multiple
imputed using a chained equation approach [20]. It was
assumed that missing values occurred at random, which
validated the use of imputation. All tests were two-sided,
and probability values of\0.05 were considered statisti-
cally significant. All analyses were performed in STATA
14.0.
Results
After exclusion, 9342 patients were included in the anal-
yses. Table 1 summarizes the characteristics of the study
population. Median age at diagnosis was 58 years (range
20–96). The majority of patients had primary
tumours B2 cm (60%), grade II disease (44%) and no
nodal involvement (61%). Median follow-up was ten years
(interquartile range (IQR) 6.5–10.0), in which 27% of the
patients died. Forty imputed datasets were pooled using
Rubin’s rules and showed healthy convergence.
Patterns of first recurrence
Recurrence occurred in 1853 patients (20%) of which 362
patients (20%) had LR, 148 (8%) RR and 1343 (72%) DM
(Fig. 1). For the entire cohort, the risk of recurrence was
highest in the second year after diagnosis (3.9%; 95% CI
3.5–4.3), with a median DFI of 3.3 years (Fig. 2a). A
second peak was present around year 8. However, as there
was overlap in the 95% CIs, this finding was not statisti-
cally significant. For LR and DM separately, a similar risk
pattern was present. The risk of DM was 3% (95% CI
2.6–3.3) during the second year, with a median DFI of
3.2 years. The annual risk of LR showed a double peaked
pattern with a risk of 0.7% (95% CI 0.5–0.8) in year two
and 0.4% (95% CI 0.2–0.5) in year eight. Median DFI was
3.6 years (Fig. 2b). The annual risk of RR showed a single
peak of 0.3% (95% CI 0.2–0.4) in year two and decreased
thereafter. Median DFI was 3.1 years (Fig. 2b). Patients
with a recurrence around year 8–9 (second peak) had on
average a better differentiated primary tumour, positive
hormone receptor status and received more often breast
conserving therapy with radiation therapy, compared to
patients with an early recurrence around year two. Sup-
plementary Figures S1–12 illustrate the patterns of first
recurrence stratified by the different prognostic factors. The
peak in risk around year two was most pronounced for
patients with grade III tumours (Fig. S4) or negative hor-
mone status (Fig. S5), while the pattern of first recurrence
showed a more gradual decline in patients with ER-positive
tumours.
Patterns of second and third recurrence
After LR, 102 out of 362 patients (28%) developed a
second recurrence (1.1% of total population). Of those, 10
patients had another LR (10%), 12 patients RR (12%) and
80 patients DM (78%). The risk of subsequent recurrence
after LR reached its maximum of 15% (95% CI 11–20%)
in the first year after previous LR (Fig. 3a). A second peak
was present in the eighth year after previous LR (6.4%;
95% CI 0.0–13.6). However, as there were only 7 events
after a previous LR after year 7, this finding was not sta-
tistically significant. Median DFI after LR was 1.1 year
(IQR 0.3–2.5). Ninety-five percent of all subsequent
recurrences after first LR occurred between 5 weeks and
7 years.
Seventy-four out of 148 patients (50%, 0.8% of total
population) had subsequent recurrence after first RR; eight
patients had LR (11%), three patients had another RR (4%)
and 63 patients DM (85%). The proportion of patients with
recurrence after RR was significantly higher than the pro-
portion of patients with recurrence after LR (p\ 0.001).
The risk of second recurrence after RR was highest in the
first year (2.7%; 95% CI 1.8–3.6) (Fig. 3b). Median DFI
after RR was 1.1 year (IQR 0.6–2.2). After RR, 95% of all
subsequent recurrences occurred between 6 weeks and
5 years after diagnosis of the first.
Eighteen patients (55%, 0.2% of the total population)
with two previous LR or RR (N = 33) developed a third
recurrence. Seven patients (39%) had two previous LRs,
two patients (11%) had two previous RRs and nine patients
(50%) had previous LR and RR.
Prognostic factors for first and subsequent
recurrences
In univariable analysis, age at diagnosis, size and grade of
the primary tumour, lymph node status, multifocality and
chemotherapy were statistically significant prognostic fac-
tors for first recurrence. Multivariable analysis demon-
strated that[3 positive lymph nodes was the most
important prognostic factor for occurrence of overall first
Breast Cancer Res Treat (2017) 165:709–720 711
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Table 1 Patient, tumour and primary treatment characteristics categorized by subsequent recurrence
Characteristic No recurrence
(N = 7489)
First recurrence DM
(N = 1343)
First recurrence LR/RR
(N = 510)
Second recurrence LR/RR
(N = 52)
Total
(N = 9342)
N % N % N % N % N %
Age at diagnosis
\40 410 5.5 126 9.4 57 11.2 3 5.8 593 6.4
40–49 1455 19.4 293 21.8 106 20.8 6 11.5 1854 19.9
60–74 4625 61.8 749 55.8 296 58.0 37 71.2 5670 60.7
C75 999 13.3 175 13.0 51 10.0 6 11.5 1225 13.1
Tumour size
B2 cm 4772 63.7 523 38.9 285 55.9 24 46.2 5580 59.7
2–5 cm 2484 33.2 728 54.2 201 39.4 24 46.2 3413 36.5
[5 cm 177 2.4 77 5.7 15 2.9 3 5.8 269 2.9
Unknown 56 0.8 15 1.1 9 1.8 1 1.9 80 0.9
Grade
I 1660 22.2 96 7.2 91 17.8 3 5.8 1847 19.8
II 3006 40.1 534 39.8 187 36.7 22 42.3 3727 39.9
III 2122 28.3 602 44.8 180 35.3 25 48.1 2904 31.1
Unknown 701 9.4 111 8.3 52 10.2 2 3.9 864 9.3
Histology
Invasive ductal 5948 79.4 1096 81.6 408 80.0 43 82.7 7452 79.8
Invasive lobular 801 10.7 158 11.8 57 11.2 6 11.5 1016 10.9
Other 740 9.9 89 6.6 45 8.8 3 5.8 874 9.4
Lymph nodes
Negative 4772 63.7 509 37.9 318 62.4 24 46.2 5599 59.9
1–3 positive 1972 26.3 424 31.6 138 27.1 21 40.4 2534 27.1
4–9 positive 607 8.1 401 29.9 41 8.0 7 13. 1049 11.2
Unknown 138 1.8 9 0.7 13 2.6 0 0.0 160 1.7
Hormone status
ER and PR- 1152 15.4 325 24.2 130 25.5 14 26.9 1607 17.2
ER/PR? 6025 80.5 960 71.5 366 71.7 38 73.1 7351 78.7
Unknown 312 4.2 58 4.3 14 2.8 0 0.0 384 4.1
Multifocality
No 6269 83.7 1061 79.0 434 85.1 41 78.9 7764 83.1
Yes 693 9.25 187 13.9 46 9.0 6 11.5 926 9.9
Unknown 527 7.0 95 7.1 30 5.9 5 9.6 652 7.0
Surgery type
BCS 4246 56.7 581 43.3 279 54.7 22 42.3 5106 54.7
Mastectomy 3243 43.3 762 56.7 231 45.3 30 57.7 4236 45.3
Microscopic residue
No 7083 94.6 1231 91.7 479 93.9 50 96.2 8793 94.1
Yes 250 3.3 50 3.7 16 3.1 1 1.9 316 3.4
Unknown 156 2.1 62 4.6 15 2.9 1 1.9 233 2.5
Chemotherapy
No 5057 67.5 660 49.1 350 68.6 34 65.4 6067 64.9
Yes 2432 32.5 683 50.9 160 31.4 18 34.6 3275 35.1
Radiation therapy
No 2631 35.1 421 31.4 207 40.6 26 50.0 3259 34.9
Yes 4858 64.9 922 68.7 303 59.4 26 50.0 6083 65.1
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Table 1 continued
Characteristic No recurrence
(N = 7489)
First recurrence DM
(N = 1343)
First recurrence LR/RR
(N = 510)
Second recurrence LR/RR
(N = 52)
Total
(N = 9342)
N % N % N % N % N %
Endocrine therapy
No 4370 58.4 643 47.9 368 72.2 30 57.7 5381 57.6
Yes 3119 41.7 700 52.1 142 27.8 22 42.3 3961 42.4
LR local recurrence, RR regional recurrence, DM distant metastasis, ER oestrogen receptor, PR progesterone receptor, BCS breast conserving
surgery
Fig. 1 Flow chart of first and
subsequent recurrences.
Abbreviations: LR local
recurrence, RR regional
recurrence, DM distant
metastasis
Fig. 2 Hazard of a all first recurrences, and b first LR and RR during 10 years of follow-up. Abbreviations: LR local recurrence, RR regional
recurrence, DM distant metastasis
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recurrence (HR 3.7, compared to N0), followed by
age\40 years and tumour size[5 cm. Younger age,
negative hormone status, BCS and no endocrine therapy
were most influential factors for first LR, and besides these,
also primary tumour size and radiation therapy for first RR
(Table 2). Tumour grade II/III and[3 positive lymph
nodes displayed the highest HRs for first DM. With 102
observed events after first LR and 74 observed events after
first RR, the number of variables in the multivariable
analyses for subsequent recurrence after LR and RR was
set to ten and seven, respectively (Table 3). Prognostic
factors for recurrence after LR were larger primary tumour
size, positive lymph nodes and higher grade. Larger pri-
mary tumour size, multifocality and shorter DFI to first RR
were prognostic factors for recurrence after RR. With only
33 patients at risk and 18 events, we did not have
enough power to identify prognostic factors for a third
recurrence.
Survival after the primary tumour
and after recurrence
Ten-year survival after the primary tumour differed sig-
nificantly (p\ 0.001) with 82% for women without
recurrence, compared to 61, 41 and 20% for women with
local, regional or distant recurrence, respectively (Supple-
mentary Figure S14). There was also a significant differ-
ence in survival after the first (p\ 0.001) and second
recurrence (p = 0.021). The ten-year survival after a first
local, regional or distant recurrence was 47, 31 and 5%,
respectively (Supplementary Figure S15). After a first local
or regional recurrence, the ten-year survival was 21, 15 and
9% for local, regional or distant second recurrences,
respectively (Supplementary Figure S16).
Discussion
We investigated the pattern of site-specific recurrence and
identified prognostic factors for first and subsequent
recurrences during a follow-up of ten years using data from
9342 women treated for primary invasive breast cancer.
The pattern of first recurrence was comparable for LR, RR
and DM with a major peak in the second year after starting
follow-up. The pattern, as well as identified prognostic
factors for overall first recurrence, seemed to be dominated
by the high percentage of DM. When recurrence was
analysed according to site, a difference in identified prog-
nostic factors was present. The hazard of subsequent
recurrences after LR and RR both declined towards the end
of follow-up. The risk of developing a second recurrence
was significantly higher after RR than after LR. And after a
second recurrence, more than half of the women were
diagnosed with a third.
The pattern of first recurrence is consistent with previ-
ous studies [10–12, 16]. As more aggressive tumours recur
earlier, individuals with these type of tumours are thereby
censored, leaving only patients with tumours that grow
more slowly and have more favourable characteristics. This
leads to an early peak in the recurrence risk and keeps long-
term recurrence rates much lower [21]. In our data, a
second peak in the hazard of recurrence was present
between year eight and nine. This pattern was present in
the different recurrence types as well as in different sub-
groups (see Supplementary Figs. S1–13). However, as
there were only 299 events between the years 7–10 and the
95% CIs around the hazard showed overlap, this finding is
not statistically significant. Jatoi et al. [11] observed a
second peak around year five and hypothesized influence
from interval censoring as patients were followed clinically
with regular intervals in this period. Yin et al. [12] report a
Fig. 3 Hazard of subsequent (second) recurrence after a first LR, and b first RR. Abbreviations: LR local recurrence, RR regional recurrence,
DM distant metastasis
714 Breast Cancer Res Treat (2017) 165:709–720
123
Table 2 Prognostic factors for site-specific first recurrence during 10 years of follow-up in women with stage I–III invasive breast cancer
(n = 9342)
Characteristic LR (362 events) RR (148 events)
Univariable Multivariable Univariable Multivariable
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Age (years)
\40 Ref Ref Ref Ref
40–49 0.67 0.45–0.99 0.045 0.59 0.40–0.88 0.009 0.34 0.19–0.61 \.001 0.35 0.19–0.63 \.001
50–74 0.54 0.38–0.78 0.001 0.43 0.30–0.61 \.001 0.44 0.27–0.70 0.001 0.42 0.25–0.71 0.001
C75 0.72 0.46–0.12 0.141 0.62 0.39–0.99 0.043 0.25 0.11–0.54 \.001 0.13 0.05–0.32 \.001
Tumour size
B2 cm Ref Ref Ref
2–5 cm 1.09 0.88–1.35 0.441 2.05 1.47–2.86 \.001 2.18 1.51–3.15 \.001
[5 cm 0.92 0.45–1.86 0.814 2.65 1.22–5.77 0.014 2.72 1.13–6.57 0.026
Grade
I Ref Ref Ref*
II 0.95 0.72–1.26 0.731 1.69 0.96–2.99 0.069 1.18 0.81–1.72 0.398
III 1.05 0.79–1.39 0.751 3.35 1.94–5.77 \.001 1.28 0.84–1.96 0.254
Lymph nodes
Negative Ref Ref* Ref Ref
1–3 positive 1.04 0.82–1.32 0.738 1.16 0.95–1.42 0.133 0.95 0.65–1.39 0.796 0.86 0.57–1.29 0.464
[3 positive 0.91 0.62–1.34 0.626 0.88 0.64–1.21 0.420 0.89 0.49–1.62 0.693 1.00 0.51–1.96 0.999
Endocrine status
ER&PR negative Ref Ref* Ref Ref*
ER/PR positive 0.67 0.52–0.86 0.001 1.59 1.27–2.00 0.001 0.35 0.25–0.49 \.001 0.85 0.61–1.20 0.364
Histology
Ductal Ref Ref Ref Ref*
Lobular 1.17 0.85–1.60 0.329 1.21 0.88–1.66 0.246 0.69 0.38–1.24 0.213 1.03 0.69–1.53 0.890
Other 1.05 0.74–1.48 0.797 0.99 0.69–1.41 0.950 0.58 0.30–1.14 0.116 0.85 0.53–1.37 0.505
Multifocality
No Ref Ref Ref Ref
Yes 0.98 0.69–1.39 0.908 1.12 0.77–1.62 0.562 0.78 0.43–1.41 0.41 0.62 0.34–1.13 0.120
Surgery type
Breast conserving Ref Ref* Ref
Mastectomy 0.87 0.70–1.08 0.197 0.74 0.63–0.87 \.001 2.17 1.56–3.02 \.001
Residual disease
No Ref Ref Ref
Microscopic 0.92 0.51–1.68 0.794 0.99 0.40–2.41 0.979 1.44 0.58–3.57 0.437
Chemotherapy
No Ref Ref Ref
Yes 0.77 0.61–0.97 0.024 1.07 0.77–1.50 0.673 0.67 0.42–1.05 0.081
Radiation therapy
No Ref Ref Ref
Yes 0.9 0.72–1.11 0.331 0.43 0.31–0.60 \.001 0.42 0.29–0.60 \.001
Endocrine therapy
No Ref Ref* Ref
Yes 0.47 0.37-0.59 \.001 0.62 0.51–0.75 \.001 0.67 0.47–0.94 \.001
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Table 2 continued
Characteristic DM (1343 events) All (1853 events)
Univariable Multivariable Univariable Multivariable
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Age (years)
\40 Ref Ref Ref*
40–49 0.69 0.56–0.85 \.001 0.65 0.54–0.77 \.001 0.83 0.73–0.95 0.007
50–74 0.58 0.48–0.70 \.001 0.55 0.47–0.65 \.001 0.84 0.74–0.96 0.008
C75 0.82 0.65–1.03 0.087 0.73 0.60–0.89 0.002 0.81 0.68–0.96 0.016
Tumour size
B2 cm Ref Ref* Ref Ref*
2–5 cm 2.60 2.33–2.91 \.001 1.27 1.16–1.39 \.001 2.15 1.95–2.36 \.001 1.22 1.14–1.32 \.001
[5 cm 3.71 2.92–4.72 \.001 1.23 1.01–1.51 0.036 2.87 2.31–3.56 \.001 1.31 1.09–1.56 0.003
Grade
I Ref Ref* Ref Ref*
II 2.70 2.18–3.34 \.001 1.42 1.25–1.63 \.001 1.93 1.64–2.26 \.001 1.24 1.12–1.37 \.001
III 4.22 3.43–5.19 \.001 1.50 1.30–1.73 \.001 2.89 2.48–3.38 \.001 1.22 1.09–1.36 \.001
Lymph nodes
Negative Ref Ref* Ref Ref*
1–3 positive 1.94 1.71–2.21 \.001 1.25 1.14–1.37 \.001 1.59 1.43–1.77 \.001 1.20 1.11–1.31 \.001
[3 positive 5.45 4.78–6.22 \.001 1.78 1.59–1.99 \.001 3.71 3.30–4.16 \.001 1.61 1.44–1.79 \.001
Endocrine status
ER and PR negative Ref Ref* Ref
ER/PR positive 0.56 0.50–0.63 \.001 1.40 1.23–1.60 \.001 0.56 0.50–0.62 \.001
Histology
Ductal Ref Ref* Ref
Lobular 1.05 0.89–1.24 0.582 1.03 0.91–1.17 0.61 1.04 0.90–1.20 0.590
Other 0.67 0.54–0.83 \.001 0.89 0.77–1.04 0.155 0.73 0.61–0.87 \.001
Multifocality
No Ref Ref Ref Ref
Yes 1.5 1.29–1.75 \.001 1.19 1.01–1.40 0.037 1.34 1.16–1.53 \.001 1.25 1.09–1.44 0.002
Surgery type
Breast conserving Ref Ref Ref
Mastectomy 1.79 1.61–1.99 \.001 1.41 1.25–1.58 \.001 1.58 1.44–1.73 \.001
Residual disease
No Ref
Microscopic 1.16 0.87–1.53 0.311
Chemotherapy
No Ref Ref Ref*
Yes 1.93 1.74–2.15 \.001 1.56 1.42–1.71 \.001 0.88 0.80–0.96 0.006
Radiation therapy
No Ref Ref
Yes 1.09 0.97–1.22 0.161 0.97 0.88–1.06 0.478
Endocrine therapy
No Ref Ref
Yes 1.47 1.32–1.63 \.001 1.12 1.03–1.23 0.012
LR local recurrence, RR regional recurrence, DM distant recurrence, HR hazard ratio, CI confidence interval, ER oestrogen receptor, PR
progesterone receptor, Ref. reference group
* time-dependent variable in analysis
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Table 3 Prognostic factors for subsequent recurrence after previous LR or RR
Characteristic Event after LR (n = 362, 102 events) Event after RR (n = 148, 74 events)
Univariable Multivariable Univariable Multivariable
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Age (years)
\40 Ref. Ref Ref Ref
40–49 0.9 0.44–1.85 0.772 1.06 0.50–2.24 0.889 1 0.43–2.31 0.999 0.89 0.38–2.11 0.793
50–74 0.83 0.43–1.58 0.567 1.04 0.52–2.09 0.904 1.19 0.61–2.35 0.609 1.87 0.90–3.88 0.093
C75 1.75 0.80–3.83 0.158 1.47 0.62–3.46 0.378 0.21 0.03–1.67 0.141 0.29 0.04–2.29 0.240
Tumour size
B2 cm Ref. Ref Ref Ref
2–5 cm 3.28 2.17–4.95 \.001 3.01 1.91–4.74 0.000 1.04 0.65–1.67 0.865 0.83 0.50–1.38 0.467
[5 cm 7.85 3.29–18.74 \.001 2.60 0.95–7.10 0.062 1.34 0.41–4.38 0.625 1.64 0.49–5.54 0.426
Grade
I Ref. Ref Ref
II 2.31 1.06–5.04 0.036 1.25 0.55–2.83 0.595 0.91 0.41–2.04 0.825
III 5.72 2.71–12.07 \.001 3.31 1.49–7.37 0.003 1.04 0.48–2.23 0.922
Lymph nodes
Negative Ref. Ref Ref
1–3 positive 2.98 1.92–4.64 \.001 1.94 1.20–3.14 0.007 1.07 0.62–1.82 0.816
[3 positive 7.03 4.05–12.21 \.001 3.23 1.65–6.30 0.001 2.25 1.01–4.98 0.047
Hormone status
ER&PR- Ref. Ref* Ref Ref
ER/PR? 0.41 0.27–0.62 \.001 0.6 0.41–0.96 0.032 0.58 0.36–0.92 0.021 0.6 0.31–1.13 0.111
Histology
Ductal Ref. Ref Ref
Lobular 0.77 0.42–1.46 0.436 0.73 0.37–1.42 0.352 1.56 0.71–3.43 0.266
Other 0.15 0.04–0.62 0.009 0.14 0.03–0.60 0.008 1.09 0.40–3.01 0.867
Multifocality
No Ref. Ref Ref Ref
Yes 0.98 0.52–1.87 0.961 1.20 0.76–2.01 0.398 1.07 0.47–0.89 0.880 1.59 0.66–3.82 0.297
Surgery type
BCS Ref. Ref
Mastectomy 2.67 1.79–3.97 \.001 0.87 0.55–1.39 0.557
Residual disease
No Ref. Ref
Microscopic 0.31 0.04–2.17 0.236 0.79 0.19–1.17 0.743
Chemotherapy
No Ref. Ref
Yes 3.07 2.07–4.54 \.001 1.1 0.68–1.76 0.696
Radiation therapy
No Ref. Ref
Yes 0.58 0.39–0.86 0.007 1.56 0.98–2.46 0.058
Endocrine therapy
No Ref. Ref* Ref Ref
Yes 1.94 1.30–2.91 0.001 1.60 1.08–2.42 0.020 0.98 0.60–1.59 0.930 1.3 0.73–2.31 0.381
DFI (years)
0–1.9 Ref. Ref Ref*
2.0–3.9 0.58 0.37–0.91 0.02 0.98 0.57–1.68 0.930 0.97 0.59–1.59 0.899
4.0–5.9 0.35 0.19–0.65 \.001 0.7 0.36–1.36 0.298 2.07 1.04–4.16 0.040
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second recurrence peak near the 9.5th year and attributed
the bimodal pattern to tumour dormancy: a state in which
tumour cells are present, but disease progression not clin-
ically apparent [22]. Demicheli et al. [13] reason that
biological characteristics are responsible for the distinctive
pattern in tumour recurrence. Our findings confirm this, as
patients with late recurrence (second peak) showed more
favourable patient and tumour characteristics than patients
with early recurrence. Besides more favourable character-
istics, a previous study also found better survival for
patients with longer DFIs during five years of follow-up
[9]. As the follow-up period of patients with late recurrence
was much shorter than follow-up for patients with early
recurrence, we could not compare the amount of subse-
quent recurrences between the groups.
The peak in risk was most pronounced for patients with
grade III tumours or negative hormone status, and more
gradual in patients with ER-positive tumours. In this study,
ER-positive patients received endocrine therapy for a
maximum of five years. Present guidelines recommend
extended endocrine treatment beyond five years [23]. This
could delay or prevent most of the ER-positive recurrences
that constitute the late recurrence peak. Additionally,
efforts to improve adherence to endocrine therapy and the
introduction of aromatase inhibitors will likely flatten the
second recurrence peak [24]. In hormone receptor-positive
breast cancer, late recurrences after[20 years can occur
[25], as hormone-positive tumours have slower doubling
times and might be suppressed for a prolonged time by
endocrine therapy [26]. Also, there may be influence of
immune surveillance in controlling progression [27].
Although patients with first recurrence eight to nine years
after starting follow-up were more often hormone receptor
positive, there was no significant difference in percentage
receiving endocrine therapy when comparing patients with
early and late recurrences.
Consistent with previous studies, younger age, larger
primary tumour and higher grade were important prog-
nostic factors for first recurrence [4, 8, 10]. The HRs of the
prognostic factors for subsequent recurrence after LR or
RR were higher than those for first recurrence, as can be
explained by the higher incidence. With a highest HR of
3.7 for first recurrence ([3 positive nodes, compared N0),
it is impossible to appoint one or just a few prognostic
factors that can be used for risk stratification. Thrift et al.
[28] state that in the case of relative risk, factors should be
higher than ten for good prediction of individual risk. In the
absence of a ‘perfect predictor’, multiple factors need to be
taken into account for risk prediction and subsequent fol-
low-up.
With only 33 patients at risk and 18 events after two
previous LRs or RRs, it was hard to identify prognostic
factors for third recurrence. The number of events deter-
mines the statistical strength of a multivariable analysis. A
Table 3 continued
Characteristic Event after LR (n = 362, 102 events) Event after RR (n = 148, 74 events)
Univariable Multivariable Univariable Multivariable
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
6.0–7.9 0.15 0.05–0.41 \.001 0.58 0.25–1.33 0.198 3.94 1.42–10.96 0.009
8.0–10.0 0.29 0.10–0.82 0.02 0.25 0.03–1.83 0.170 4.34 0.24–76.81 0.317
Surgery of recurrence
No Ref. Ref Ref Ref
Yes 0.33 0.20–0.55 \.001 0.40 0.21–0.75 0.005 0.52 0.33–0.82 0.005 0.42 0.26–0.70 0.001
Chemotherapy of recurrence
No Ref. Ref Ref
Yes 1.03 0.60–1.76 0.92 0.66 0.37–1.19 0.170 1.31 0.83–2.08 0.245
Radiation therapy of recurrence
No Ref. Ref Ref
Yes 2.02 1.37–2.98 \.001 1.51 0.96–2.39 0.076 1.4 0.87–2.26 0.169
Endocrine therapy of recurrence
No Ref. Ref Ref
Yes 0.69 0.46–1.04 0.07 0.61 0.38–0.98 0.040 0.64 0.36–1.17 0.148
LR local recurrence, RR regional recurrence, HR hazard ratio, CI confidence interval, BCS breast conserving surgery, PR progesterone receptor,
Ref. reference group, DFI disease-free interval
* time-dependent variable in analysis
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commonly used rule of thumb based on simulation studies
[29–31], is a ratio of at least ten to twenty events per
explaining variable to maintain the validity of the model.
However, there are others suggesting that this rule is too
conservative [32].
Strengths of this study include the large sample size, a
follow-up duration of ten years and inclusion of an unse-
lected patient cohort from the population-based NCR,
representative for the majority of breast cancer patients. By
extracting data in retrospect from patient medical records,
time of recurrence diagnosis was determined with high
accuracy. This is important in avoiding bias in the shape of
hazard [33]. We used extended regression, while the pro-
portional hazards assumption did not hold for several
variables, as could be expected with long-term follow-up
[34]. Changes and improvements in diagnostic procedures
and treatment have resulted in a sustained decline in breast
cancer recurrence [35], which means data from 2003 may
not be representative for the current risk of recurrence.
Because regular registration of Human Epidermal Recep-
tor-2 (HER-2) status initiated in 2005, this prognostic
factor could not be included in the analysis. However, as
trastuzumab treatment for HER-2-positive patients is cur-
rently standard practice, the prognostic value of HER-2 in
models is less important [4]. Inclusion of more recurrence
characteristics than site and treatment, could likely result in
better risk prediction of subsequent recurrence than models
largely based on primary tumour characteristics. As it is
hard to distinguish second primary breast cancer from
contralateral recurrence, only ipsilateral and distant recur-
rence were taken into account in the analysis, which might
have resulted in underestimation of the actual recurrence
rate [36]. In addition, even though second primary tumours
are of importance for follow-up, the focus of this study was
on recurrence of the primary tumour and their corre-
sponding characteristics. Although subsequent recurrence
does occur in a small subset of patients diagnosed with
DCIS, these were excluded from the current analysis
[37, 38]. During the follow-up period, 27% of the patients
died. The 10-year survival after the primary tumour, as
well as after the first and second recurrence differed sig-
nificantly per recurrence type. For more details on factors
influencing 5-year survival after recurrence, the reader is
referred to Witteveen et al. [9]. Competing risk analysis
was not considered relevant as breast cancer specific
mortality was assumed to be only possible after DM, and
further recurrence after DM were not taken into account.
Time to subsequent recurrence was counted from diagnosis
of first recurrence, instead of three months afterwards, as
the time until second recurrence is on average much shorter
(median DFI 1.1 years, compared to 3.3 for first recur-
rence). This means almost half of all possible second
recurrences will be diagnosed in the first year of follow-up,
in which most patients already have more hospital visits
due to prolonged treatment or aftercare. Also, more than
80% of the second recurrences after LR or RR, and almost
80% of third recurrences are DM, of which early detection
is not aim of regular follow-up care, as earlier detection
will not (yet) result in better prognosis.
This study is, to the best of our knowledge, the first
analysis that takes site-specific first and also subsequent
recurrence after LR and RR into account. The pattern of
first recurrence was similar for LR, RR and DM with a
major peak in recurrence risk around the second year post-
diagnosis. The hazard of subsequent recurrence was higher
if the first recurrence was RR compared to LR. As most
risk factors only have modest effects, multiple risk factors
need to be taken into account for risk prediction and sub-
sequent follow-up decisions. Although the percentage of
patients with first recurrence that develop a second recur-
rence is high, the percentage among all breast cancer
patients remains very low (1.9% during ten years). As
almost 50% of the second recurrences will be diagnosed in
the first follow-up year, combined with the low absolute
number of second recurrences, more intensive follow-up
for detection of subsequent recurrence is not likely to be
(cost-)effective.
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